Table 4.
Characteristics | >1 | 0 or 1 | p | 1 | p | 0 | p |
---|---|---|---|---|---|---|---|
n = 7 | n = 57 | (>1 vs. 0 or 1) | n = 45 | (>1 vs. 1) | n = 12 | (>1 vs. 0) | |
Age | |||||||
Median (range) | 56.3 (48.5–72.1) | 56.8 (31.0–81.4) | 0.389 * | 56.1(31.0–80.3) | 0.318 * | 58.9 (42.0–81.4) | ns * |
FIGO Stage a | |||||||
III | 6 (85.7) | 45 (78.9) | 35 (77.8) | 10 (83.3) | |||
IV | 1 (14.3) | 12 (21.1) | 10 (22.2) | 2 (16.7) | |||
Tumor Grade | |||||||
G2 | 3 (42.9) | 15 (26.3) | 0.391 | 11 (24.4) | 0.369 | 4 (33.3) | 1.000 |
G3 | 4 (57.1) | 42 (73.7) | 34 (75.6) | 8 (66.7) | |||
RD at PDS | |||||||
0 | 4 (57.1) | 29 (50.9) | 1.000 | 22 (48.9) | 1.000 | 7 (58.3) | 1.000 |
<1 cm | 3 (42.9) | 28 (49.1) | 23 (51.1) | 5 (41.7) | |||
Lymph Node involvement | |||||||
Negative | 2 (28.6) | 8 (14.0) | 0.092 | 6 (13.3) | 0.100 | 2 (16.7) | 0.167 |
Positive | 1 (14.3) | 33 (57.9) | 26 (57.8) | 7 (58.3) | |||
Unknown | 4 (57.1) | 16 (28.1) | 13 (28.9) | 3 (25.0) | |||
Platinum sensitivity b | |||||||
Refractory | 2 (28.6) | 1 (1.8) | 0.019 | 0 (0.0) | 0.004 | 1 (8.3) | 0.515 |
Resistant | 1 (14.3) | 12 (21.0) | 10 (22.2) | 2 (16.7) | |||
Intermediate | 2 (28.6) | 17 (29.8) | 15 (33.3) | 2 (16.7) | |||
Sensitive | 2 (28.6) | 26 (45.6) | 19 (42.2) | 7 (58.3) |
* Mann-Whitney test; a One patient with IIIB stage was included in IIIC (III vs. IV). a One patient with tumor grade G2-G3 was included in grade G3. b One patient was not evaluated due to loss at follow up. ns: not significant; FIGO: Fédération Internationale de Ginécologie et d’Obstetrique; RD: Residual Disease; PDS: primary debulking surgery. Comparisons were performed between the sub-group with 2 mutated genes (>1) and patients with: 1 mutated gene or not mutated (>1 vs. 0 or 1); patients with 1 mutated gene (>1 vs. 1); patients not mutated (>1 vs. 0). Fisher’s Exact test, Chi-squared test or Mann-Whitney test were used in the analyses; p values <0.05 were considered significant and were depicted in bold.